Program Schedule

Antimicrobial Resistance: Novel Agents and Approaches to Gram-negative Infections

Thursday, October 9, 2014: 12:30 PM-2:00 PM
Room: The Pennsylvania Convention Center: IDExpo Hall BC

Learning Objectives:


Target Audience: Vaccinologists, Scientists, Researchers, Public health practitioners, Pharmacists, Nurses, Microbiologists, Members-in-training, Medical students and residents, Lab personnel, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Infection preventionists, Hospital epidemiologists, HIV specialists, HIV clinicians, Health care workers, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

S-649266, a Novel Siderophore Cephalosporin: Efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 gram dose with 1 hour and 3 hours infusion
Masakatsu Tsuji, Ph.D ; Christine Singley ; Tsukasa Horiyama ; Rio Nakamura ; Roger Echols, M.D ; Stephen Rittenhouse, Ph.D ; Yoshionori Yamano, Ph.D ; Jingoro Shimada, M.D, Ph.D
  • 248_IDWeek(#03).pdf (3.9 MB)
  • 249
    Activity of Plazomicin Against Contemporary Isolates of Enterobacteriaceae from New York City
    Olawole Olafisoye, MD ; Marie Abdallah, MD ; Christopher Cortes, MD ; Carl Urban, PhD ; David Landman, MD ; John Quale, MD
    Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Phase 3 Ceftolozane/Tazobactam Study
    Benjamin Miller, PharmD ; Myra Popejoy, PharmD ; Ellie Hershberger, PharmD ; Judith Steenbergen, PhD ; Bhavin Busa, MS ; Guojun Yuan, PhD ; Robert Mensah, PhD ; Ian Friedland, MD ; John Alverdy, MD, FACS
    S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria including Multidrug-Resistant Strains
    Masakatsu Tsuji, Ph.D ; Akinobu Ito, Ph.D ; Rio Nakamura ; Yoshionori Yamano, Ph.D ; Jingoro Shimada, M.D, Ph.D
  • 252_IDWeek(#02).pdf (6.0 MB)
  • 253
    Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City
    Marie Abdallah, MD ; Olawole Olafisoye, MD ; Christopher Cortes, MD ; Carl Urban, PhD ; David Landman, MD ; John Quale, MD
    In Vitro Activity of Ceftazidime in Combination with Avibactam versus 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013
    Andrew Walkty, MD ; Melanie Decorby, MSc ; Heather J. Adam, PhD ; Philippe LagacÚ-Wiens, MD ; James Karlowsky, PhD ; Daryl Hoban, PhD ; George Zhanel, PhD
    S-649266, a Novel Siderophore Cephalosporin: Mechanisms of enhanced activity and beta-lactamase stability
    Masakatsu Tsuji, Ph.D ; Akinobu Ito, Ph.D ; Tsukasa Horiyama ; Norio Fukuhara, Ph.D ; Rio Nakamura ; Yoshionori Yamano, Ph.D ; Jingoro Shimada, M.D, Ph.D ; Yoshikazu Ishii, PhD ; Keizo Yamaguchi, M.D, Ph.D ; Kazuhiro Tateda, MD, PhD
  • 256_IDWeek(#01).pdf (8.6 MB)
  • 258
    S-649266 Modeling and Simulation for Prediction of Efficacy and Dose Optimization
    Takayuki Katsube, Ph.D. ; Toru Ishibashi, Ph.D. ; David Tenero, Pharm.D. ; Toshihiro Wajima, Ph.D.
  • 258_IDWeek(#04).pdf (5.4 MB)
  • 259
    IgG mAbs against Klebsiella pneumoniae K1-CPS as a possible new therapeutic approach
    Elizabeth Diago-Navarro, PhD ; Isabel Calatayud-Baselga ; Amaia Ulacia-Hernando ; Bettina Fries, MD
    Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae
    Myra Popejoy, PharmD ; Daniel Cloutier, PharmD ; Jennifer Huntington, PharmD ; Judith Steenbergen, PhD ; Ellie Hershberger, PharmD ; Obiamiwe Umeh, MD, MSc ; Benjamin Miller, PharmD ; Keith Kaye, MD, MPH

    CME Credits:

    ACPE Credits:

    ACPE Number:

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, All Rights Reserved.

    Follow IDWeek